Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Aug 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 07 Feb 2018 Planned End Date changed from 1 Feb 2019 to 1 Feb 2021.
- 07 Feb 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.